background
background

Meeting Your Molecular Diagnostics Needs

ACT Genomics offers a broad range of genomic assays – from comprehensive to smaller targeted panels – that empower physicians with evidence-based genomic insights for disease management.

Why ACT Genomics?

patients

High success rate of sequencing to result

Enhanced laboratory protocols to achieve high-performance sequencing to result even with a limited specimen.

patients

Up-to-date database with clinical actionability

Periodically updated databases to ensure relevant clinical application.

patients

On-time result delivery with support

Short TAT to meet physicians and patients' time constraints with post-service support i.e., 1-on-1 report consultation.

patients

A trusted brand with high credibility & reliability

Internationally recognized and engaged by major cancer hospitals and clinics.

Our Tests & Their Focuses

Wide range of genomic profiling panels, tailored for different focuses and clinician needs, requiring either tissue and/or liquid biopsy.

TREATMENT SELECTION

TREATMENT SELECTION

DISEASE MONITORING

DISEASE MONITORING

RISK PREDICTION

Risk Prediction

Compare Our Tests

Find the most suitable test for you

What the test does

Provides comprehensive genetic information on potential therapeutic response (i.e. to targeted therapy, chemotherapy, immunotherapy)

 

Incorporates pathway-based analysis for a holistic overview & therapeutic recommendations

 

Focuses on clinically recommended biomarkers for targeted therapies

Focuses on biomarkers associated with lung cancer for targeted therapy

Identifies clinically relevant and future potential fusion biomarkers

Provides comprehensive genetic information for Somatic and/or Germline BRCA1/2 mutations (2 panels available: tissue or blood based)

Determines BRCA 1/2, LOH and HRD status for PARP inhibitor treatment

Monitors disease burden and treatment response/resistance

Monitors disease burden and treatment response/resistance

Monitors disease burden and treatment response/resistance

Monitors disease burden and treatment response/resistance

Provides targetable drug options using cerebrospinal fluid (CSF)

Evaluates and manages hereditary cancer risk#

Cancer types covered

All types of solid tumors (including common & rare cancers)

Common cancer types: lung cancer, gastric cancer, colon cancer, prostate cancer, etc.

Lung cancer

All types of solid tumors

BRCA-associated cancers: ovarian cancer, breast cancer, pancreatic cancer, prostate cancer

Ovarian cancer and HRD-/HRR-related cancer types

Other solid tumors (Pan-cancer)

Lung cancer

Breast cancer

Colon cancer

Brain metastases from lung cancer, breast cancer, etc.

9 major hereditary cancers & 11 hereditary cancer syndromes

Genes covered

440 cancer-related genes (including 13 fusion genes)

40 actionable genes (including 13 fusion genes)

13 lung-cancer-related genes (including 8 fusion genes)

13 fusion genes (covering both known & novel fusion transcripts)

BRCA1 & BRCA2

24 HRR-related genes (including BRCA1/2)

50 cancer-related genes

11 Lung-cancer-related genes

8 Breast-cancer-related genes

13 Colon-cancer-related genes

40 actionable genes

67 hereditary-cancer-related genes

Type of patients

All major solid tumors

 

Newly diagnosed, advanced, recurrent and metastatic cancer

Common solid tumors with biomarker focus

 

Newly diagnosed, advanced, recurrent and metastatic cancer

Non small cell lung cancer (NSCLC)

 

Newly diagnosed and metastatic cancer

All major solid tumors

 

Newly diagnosed, advanced, recurrent and metastatic cancer

Considering PARP inhibitor treatment

 

Newly diagnosed, advanced, recurrent and metastatic cancer

Considering PARP inhibitor treatment

 

Newly diagnosed, advanced, recurrent and metastatic cancer

Other solid tumors (Pan-cancer)

 

Newly diagnosed, advanced, recurrent and metastatic cancer

Lung cancer

 

Newly diagnosed, advanced, recurrent and metastatic cancer

Breast cancer

 

Newly diagnosed, advanced, recurrent and metastatic cancer

Colon cancer

 

Newly diagnosed, advanced, recurrent and metastatic cancer

All major solid tumors with brain metastases

 

Advanced, recurrent and metastatic cancer

An individual with a family history of cancer

 

An individual with multiple cancers

 

An individual with an early-onset or a rare cancer

 

An individual who is concerned about their risk of getting hereditary cancer

 

Couples who intend to start a family and want to know if they carry a cancer-causing genetic mutation§

Turnaround time ( *starting from the date of receipt of approved samples at our CAP-accredited laboratory)

10 working days*

8 working days*

8 working days*

10 working days*

10 working days*

10 working days*

10 working days*

10 working days*

10 working days*

10 working days*

8 working days*

12 working days*

Specimen requirements *refer to our specimen instructions

Tumor tissue (FFPE)

Tumor tissue (FFPE)

Tumor Tissue (FFPE)

Tumor tissue (FFPE)

Tumor tissue (FFPE) or Blood

Tumor tissue (FFPE) 

Cerebrospinal fluid (CSF)

Blood 

Mutational profiling of HRR genes can be applied to other cancer types such as breast, pancreatic or prostate cancers.

# Genetic counselling is highly recommended prior to taking a genetic test for hereditary cancer screening.

§ For family planning, both members of the couple need to be tested so that the genetic counsellor can provide a complete review and recommendations.

 

Doctors View : Treatment with Better Precision through Cancer Genetic Profiling

In the era of precision medicine, what are the advanced diagnostic tools available for cancer management? We ask oncologists to share their views and experiences.

Clinical News

How to Order

patients

Step 1

Contact Us

Contact your local ACTG representative or email us at service.sg@actgenomics.com to order a test.

patients

Step 2

Prepare Specimen & Forms

Prepare tumor (FFPE) and/or blood specimen, as well as the associated documentation.

patients

Step 3

Courier of Specimen Kit

Contact an ACTG representative for assistance with logistics and shipping documentation.

patients

Step 4

Results Report Sent

An electronic version of the results report will be emailed to you. A 1-on-1 report consultancy will be provided upon request.

If you have any questions on how to order our tests, please feel free to contact us.

FAQs

  • How do I decide which ACT Genomics panel is the most suitable for my patients?

    Our ACTG staff will be able to advise you on the most appropriate panel based on the information you provide, such as cancer type, objectives of the test, biomarker/s of interest, financial considerations, etc.

  • How do I interpret the ACT Genomics report?

    ACT Genomics provides a 1-on-1 consultation with one of our experts to extract all the useful information that can be found from the report. In addition, our Medical Science Liaison (MSL)team is able to further assist you in finding appropriate clinical evidence based on the results in the report.

  • Why should I consider ACT Genomics instead of other providers to do the genomic testing?

    Our laboratory meets the strictest laboratory standards set out by the College of American Pathology (CAP). In addition to our CAP accreditation, ACT Genomics provides a variety of high-quality genomic tests that are focused on different requirements. This variety will provide you with the option to pick the most appropriate and cost-effective test for your patient's needs. In addition, in the rare case that your patient's sample does not meet the chosen panel requirements, you will be able to choose a more suitable panel from our extensive range. This will avoid having to waste your patient's sample and you having to search out other options (i.e., other genomic testing providers etc.).

  • Is ACT Genomics test recognized by insurance companies?

    The cost of our tests have been successfully claimed by patients. The success of reimbursement by an insurance company is also determined on several other factors namely i) insurance type and coverage chosen by the patients; ii) the reason for performing genomic testing, etc. We would recommend you encourage your patient to contact their healthcare insurance provider.

  • What kind of sample can be used for genomic testing?

    ACT Genomics is able to perform testing on the following samples: Tissue (FFPE), Blood, DNA, Cell block (≥1x106), and Cerebrospinal fluid (CSF). Tissue (FFPE) blocks and slides are the most commonly received samples and are often the preferred sample of genomic testing providers.